Hematology/Oncology

Top Story

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs
February 8, 2016

Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping” — to prevent affordable generic cancer drugs from entering the market, according to a forum article published in Blood.

These tactics also have led to an increase in drug prices so that, if available, generics can cost nearly as much as the branded product.

Breaking News

Senate health committee considers seven biomedical innovation bills

February 8, 2016
The U.S. Senate Committee on Health, Education, Labor and Pensions will consider seven bipartisan bills on biomedical innovation tomorrow, Feb. 9, at the first of three…
In the Journals

PSA testing rates differ among urologists, PCPs

February 8, 2016
PSA testing rates have declined overall since the U.S. Preventive Services Task Force made a recommendation against the test, but these declines were greater among…
FDA News

FDA grants orphan drug designation to tazemetostat for treatment of malignant rhabdoid tumors

February 8, 2016
The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the agent’s manufacturer.The…
In the Journals

Addition of lenalidomide to standard therapy fails to prolong PFS in multiple myeloma

February 8, 2016
Combination lenalidomide, melphalan and prednisone, followed by lenalidomide maintenance, did not significantly extend PFS or improve response rates compared with…
More News Headlines »
CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News CoverageVideo

VIDEO: Negative ACCORD trial results reinforce standard of care for rectal cancer

January 27, 2016
More »
Featured
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today